Epperly Melissa B,
CIK 1807359 · Chief Financial Officer · last filed 2026-10-05
Epperly Melissa B, is a Chief Financial Officer who has filed 62 SEC Form 4 insider transactions across 5 companies since 2020. The most recent filing, for ROIV, was dated Oct 5, 2026. Across all open-market trades the lifetime net is −$5.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions. 28 SEC filings were submitted jointly with Roivant Sciences Ltd.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ZNTL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PHILADELPHIA, PA 19118
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ROIV | Director | 14,954 | $36.05 | $539.1K | -$2.65M | 22 | 2026-10-05 |
| NAUT | Director | — | $2.44 | — | $0 | 5 | 2026-06-22 |
| ZNTL | Chief Financial Officer | 451,449 | $2.07 | $934.5K | -$3.15M | 23 | 2024-02-12 |
| Roivant Sciences Ltd. (ROIVW) Delisted | Director | 1,280 | $2.75 | $3.5K | $0 | 2 | 2023-07-06 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | — | $2.65 | — | $0 | 3 | 2023-06-13 |
Recent Filings
62 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-05 | ROIV | Mixed | — | -$561.7K | EDGAR |
| 2026-09-18 | ROIV | Grant (A) | +5,054 | $0 | EDGAR |
| 2026-09-17 | ROIV | Sell (S) | −4,938 | -$196.2K | EDGAR |
| 2026-09-15 | ROIV | Notice (144) | −22,688 | -$930.7K | EDGAR |
| 2026-09-14 | ROIV | Tax (F) | −2,179 | -$89.2K | EDGAR |
| 2026-07-21 | ROIV | Grant (A) | +543 | $0 | EDGAR |
| 2026-07-01 | ROIV | Mixed | — | -$531.1K | EDGAR |
| 2026-06-29 | ROIV | Notice (144) | −17,750 | -$604.7K | EDGAR |
| 2026-06-22 | NAUT | Grant (A) | — | $0 | EDGAR |
| 2026-04-21 | ROIV | Grant (A) | +670 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.